Scholtz & Company LLC Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Scholtz & Company LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 26,857 shares of the medical device company’s stock after acquiring an additional 1,059 shares during the period. DexCom makes up 1.3% of Scholtz & Company LLC’s investment portfolio, making the stock its 27th largest position. Scholtz & Company LLC’s holdings in DexCom were worth $3,045,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom during the second quarter worth $25,000. Sachetta LLC grew its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares in the last quarter. DSM Capital Partners LLC purchased a new position in DexCom during the 4th quarter valued at about $28,000. Crewe Advisors LLC bought a new stake in shares of DexCom during the first quarter valued at about $29,000. Finally, Riverview Trust Co bought a new position in shares of DexCom in the first quarter valued at approximately $32,000. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 0.5 %

NASDAQ:DXCM opened at $68.82 on Friday. The firm has a market capitalization of $27.58 billion, a P/E ratio of 44.40, a P/E/G ratio of 2.12 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company has a fifty day moving average of $83.24 and a 200 day moving average of $111.61. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.34 earnings per share. On average, research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on DXCM shares. Oppenheimer decreased their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Canaccord Genuity Group restated a “buy” rating and issued a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Baird R W downgraded DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Finally, Royal Bank of Canada lowered their target price on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $112.25.

Insider Activity

In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,483 shares of company stock valued at $201,708. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.